GGrantIndex
Sort

40,608 grants matching prostate cancer

Towards Understanding Prostate Cancer Heterogeneity

$365,372
Mark A. Rubin · Weill Medical Coll Of Cornell Univ · R01 · FY2010 · CA

Towards Understanding Prostate Cancer Heterogeneity

$365,314
Mark A. Rubin · Weill Medical Coll Of Cornell Univ · R01 · FY2008 · CA

MicroRNAs in African American Prostate Cancer

$365,305
Deepak Kumar · North Carolina Central University · U01 · FY2016 · CA

SYSTEMATIC ASSESS OF GENE EXPRESSION IN MOUSE PROSTATE

$365,269
Wake Forest University Health Sciences · R01 · FY2001 · ES

Tumor stem cells and metastatic outcomes in mouse models of prostate cancer

$365,255
Kathleen Kelly · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

A Novel Lineage Specific Metastasis Suppressor Pathway in Lung Cancer

$365,216
Don X Nguyen · Yale University · R01 · FY2015 · CA

Chlorotoxin as a Targeting Agent for Cancer Therapies

$365,200
James M Olson · Fred Hutchinson Cancer Research Center · R01 · FY2009 · CA

Chlorotoxin as a Targeting Agent for Cancer Therapies

$365,200
James M Olson · Fred Hutchinson Cancer Research Center · R01 · FY2010 · CA

Regulation of glucose metabolism to allow tumor initiation and growth

$365,160
Matthew G. Vander Heiden · Massachusetts Institute Of Technology · R01 · FY2019 · CA

TR&D 4: Revealing Microstructure: Biophysical modeling and validation for discovery and clinical care

$365,156
Els Fieremans · New York University School Of Medicine · P41 · FY2019 · EB

CALGB

$365,117
Ohio State University · U10 · FY2002 · CA

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance

$365,103
Steven P. Balk · Beth Israel Deaconess Medical Center · P01 · FY2019 · CA

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance

$365,099
Steven P. Balk · Beth Israel Deaconess Medical Center · P01 · FY2021 · CA

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance

$365,099
Steven P. Balk · Beth Israel Deaconess Medical Center · P01 · FY2020 · CA

Adhesion of Metastatic Tumor Cells in the Bloodstream

$365,089
Michael R King · Cornell University · U54 · FY2012 · CA

Chemical Glycoproteomics

$365,056
Carolyn R Bertozzi · Stanford University · R01 · FY2015 · CA

Lung Cancer Drivers and Dependencies as Therapeutic Targets

$365,049
Scott W Lowe · Sloan-Kettering Inst Can Research · P01 · FY2015 · CA

Subcellular Distribution & Regulation of ala-Adrenocepto

$365,049
Debra A. Schwinn · University Of Washington · R37 · FY2007 · HL

Lung Cancer Drivers and Dependencies as Therapeutic Targets

$365,049
Scott W Lowe · Sloan-Kettering Inst Can Research · P01 · FY2016 · CA

Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)

$365,015
Xuefeng Liu · Ohio State University · R01 · FY2020 · CA

Magnetic Resonance Elastography

$365,000
Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2003 · EB

HEI: ECLIPSE RD CYCLOTRON: CANCER: BRAIN, PROSTATE, BREAST, OVARIAN

$365,000
Sloan-Kettering Institute For Cancer Res · S10 · FY2004 · RR

P13K/PTEN/Akt signaling and the genesis of cancer

$364,986
Nissim Hay · University Of Illinois At Chicago · R01 · FY2007 · CA

Cancer stem cells and human liver cancer

$364,963
Snorri Thorgeirsson · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

ANDROGEN INDEPENDENT PROSTATE CANCER:A TRANSGENIC MODEL

$364,963
Baylor College Of Medicine · R01 · FY2002 · CA